In 2019, Shionogi in Japan patented two very similar classes of 5-pyrazolyl-ureas as TrkA inhibitors claimed as useful for treat osteoarthritis and RA, interstitial cystitis, chronic pancreatitis, prostatitis, and different type of pain such as chronic back pain, nociceptive, neuropathic, postoperative, pelvic, cancer pain, etc. In Figure 7 are reported 47 and 48 as representative compounds. This evidence concerns the gene NTRK1 and prostatitis.